[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Immuno-oncology,Leukemias: acute myeloid,Interleukin-1,FLT3,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>R. von Roemeling<\/b><sup>1<\/sup>, A. De La Fuente<sup>2<\/sup>, C. Cerchione<sup>3<\/sup>, S. Scholl<sup>4<\/sup>, J. Middeke<sup>5<\/sup>, G. Choudhary<sup>1<\/sup>, M. Lamar<sup>1<\/sup>, S. Angelides<sup>1<\/sup>, U. Platzbecker<sup>6<\/sup>; <br\/><sup>1<\/sup>Curis, Inc., Lexington, MA, <sup>2<\/sup>MD Anderson Cancer Center, Madrid, Spain, <sup>3<\/sup>Istituto Romagnolo per lo Studio dei Tumori, Meldola, Italy, <sup>4<\/sup>Universitätsklinikum Jena, Jena, Germany, <sup>5<\/sup>Technische Universität Dresden, Dresden, Germany, <sup>6<\/sup>University Hospital Leipzig, Leipzig, Germany","CSlideId":"","ControlKey":"44c3392c-018c-4590-aeb4-06f0e2ced205","ControlNumber":"10441","DisclosureBlock":"<b>&nbsp;R. von Roemeling, <\/b> <br><b>Employed by Curis Inc.<\/b> Employment. <br><b>A. De La Fuente, <\/b> <br><b>Curis Inc.<\/b> Other, Principal investigator. <br><b>C. Cerchione, <\/b> <br><b>Curis Inc.<\/b> Other, Principal investigator. <br><b>S. Scholl, <\/b> <br><b>Curis Inc.<\/b> Other, Principal investigator. <br><b>J. Middeke, <\/b> <br><b>Curis Inc.<\/b> Other, Principal investigator. <br><b>G. Choudhary, <\/b> <br><b>Curis Inc.<\/b> Employment. <br><b>M. Lamar, <\/b> <br><b>Curis Inc.<\/b> Employment. <br><b>S. Angelides, <\/b> <br><b>Curis Inc.<\/b> Employment. <br><b>U. Platzbecker, <\/b> <br><b>Curis Inc.<\/b> Grant\/Contract, Other, Principal investigator.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11617","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT150","PresenterBiography":null,"PresenterDisplayName":"Jamison Hoffman","PresenterKey":"4d363c2a-adce-47bc-b829-9f4163e58197","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT150. Trial in progress: A phase 1b single-arm, open-label, study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in acute myeloid leukemia patients in complete response with measurable residual disease","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Trial in progress: A phase 1b single-arm, open-label, study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in acute myeloid leukemia patients in complete response with measurable residual disease","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Leukemias,Minor histocompatibility antigen,Adaptive cell therapy,T cell receptor,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"M. Al Malki<sup>1<\/sup>, A. Keyzner<sup>2<\/sup>, H. Suh<sup>3<\/sup>, U. Popat<sup>4<\/sup>, C. Yi-Bin<sup>5<\/sup>, S. Gill<sup>6<\/sup>, M. Solh<sup>7<\/sup>, J. Uberti<sup>8<\/sup>, I. Isufi<sup>9<\/sup>, E. Buonomo<sup>10<\/sup>, Y. Wang<sup>10<\/sup>, J. Murray<sup>10<\/sup>, G. MacBeath<sup>10<\/sup>, <b>D. Barton<\/b><sup>10<\/sup>, S. Chattopadhyay<sup>10<\/sup>, R. Reshef<sup>11<\/sup>; <br\/><sup>1<\/sup>City of Hope Medical Center, Duarte, CA, <sup>2<\/sup>Mount Sinai Medical Center, New York, NY, <sup>3<\/sup>Hackensack University Medical Center, Hackensack, NJ, <sup>4<\/sup>MD Anderson Cancer Center, Houston, TX, <sup>5<\/sup>Massachusetts General Hospital Cancer Center, Boston, MA, <sup>6<\/sup>University of Pennsylvania School of Medicine, Philadelphia, PA, <sup>7<\/sup>Northside Hospital, Atlanta, GA, <sup>8<\/sup>Karmanos Cancer Institute, Detroit, MI, <sup>9<\/sup>Yale University School of Medicine, New Haven, CT, <sup>10<\/sup>TScan Therapeutics, Waltham, MA, <sup>11<\/sup>Columbia University Medical Center, New York, NY","CSlideId":"","ControlKey":"4d26ec8f-98d7-479f-b5c0-e31d48d18328","ControlNumber":"10590","DisclosureBlock":"<b>&nbsp;M. Al Malki, <\/b> <br><b>TScan Therapeutics<\/b> Other, Advisory.<br><b>A. Keyzner, <\/b> None..<br><b>H. Suh, <\/b> None..<br><b>U. Popat, <\/b> None.&nbsp;<br><b>C. Yi-Bin, <\/b> <br><b>TScan Therapeutics<\/b> Other, Advisory.<br><b>S. Gill, <\/b> None..<br><b>M. Solh, <\/b> None..<br><b>J. Uberti, <\/b> None..<br><b>I. Isufi, <\/b> None.&nbsp;<br><b>E. Buonomo, <\/b> <br><b>TScan Therapeutics<\/b> Employment, Stock Option. <br><b>Y. Wang, <\/b> <br><b>TScan Therapeutics<\/b> Employment, Stock Option. <br><b>J. Murray, <\/b> <br><b>Tscan Therapeutics<\/b> Employment, Stock Option. <br><b>G. MacBeath, <\/b> <br><b>Tscan Therapeutics<\/b> Employment, Stock Option. <br><b>D. Barton, <\/b> <br><b>TScan Therapeutics<\/b> Employment, Stock Option. <br><b>S. Chattopadhyay, <\/b> <br><b>TScan Therapeutics<\/b> Employment, Stock Option. <br><b>R. Reshef, <\/b> <br><b>TScan Therapeutics<\/b> Other, Advisory.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11618","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT151","PresenterBiography":null,"PresenterDisplayName":"Debora Barton, MD","PresenterKey":"0b1da6e2-d0d8-4213-a30a-572523739588","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT151. Trial in progress:A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Trial in progress:A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"NSCLC,Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI),EGFR,Cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>X. Le<\/b><sup>1<\/sup>, A. Spira<sup>2<\/sup>, S. Gadgeel<sup>3<\/sup>, Y. Yu<sup>4<\/sup>, Y. Zhao<sup>5<\/sup>, Y. Cheng<sup>6<\/sup>, J. Riess<sup>7<\/sup>, O. Juan-Vidal<sup>8<\/sup>, B. Gao<sup>9<\/sup>, K. Yoh<sup>10<\/sup>, M. Forster<sup>11<\/sup>, S. Kitazono<sup>12<\/sup>, H. Hayashi<sup>13<\/sup>, D. Planchard<sup>14<\/sup>, Y. Jiang<sup>15<\/sup>, J. Huang<sup>16<\/sup>, N. Baio<sup>16<\/sup>, M. Kowanetz<sup>16<\/sup>, S. Wang<sup>16<\/sup>, W. Leung<sup>16<\/sup>, J. Y. Hsu<sup>16<\/sup>, J. Wang<sup>17<\/sup>; <br\/><sup>1<\/sup>MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>Virginia Cancer Specialists Research Institute and Next Oncology, Fairfax, VA, <sup>3<\/sup>Henry Ford Cancer Institute, Detroit, MI, <sup>4<\/sup>Harbin Medical University Cancer Hospital, Harbin, China, <sup>5<\/sup>Henan Cancer Hospital, Zhengzhou, China, <sup>6<\/sup>Jilin Cancer Hospital, Changchun, China, <sup>7<\/sup>UC Davis Comprehensive Cancer Center, Sacramento, CA, <sup>8<\/sup>La Fe University and Polytechnic Hospital, Valencia, Spain, <sup>9<\/sup>Blacktown Cancer and Haematology Centre, Blacktown, Australia, <sup>10<\/sup>National Cancer Center Hospital East, Chiba, Japan, <sup>11<\/sup>University College London Hospitals, London, United Kingdom, <sup>12<\/sup>Cancer Institute Hospital of JFCR, Tokyo, Japan, <sup>13<\/sup>Kindai University Hospital, Osaka, Japan, <sup>14<\/sup>Institut Gustave Roussy, Department of Medical Oncology, Villejuif, France, <sup>15<\/sup>Allist Pharmaceuticals, Shanghai, China, <sup>16<\/sup>Arrivent BioPharma, Inc., Burlingame, CA, <sup>17<\/sup>Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China","CSlideId":"","ControlKey":"3ec36d9e-038e-471b-b4ed-005be265ed62","ControlNumber":"10482","DisclosureBlock":"<b>&nbsp;X. Le, <\/b> <br><b>Eli Lilly<\/b> Independent Contractor, Other, Research Funding to Institution. <br><b>EMD Serono<\/b> Independent Contractor, Travel, Other, Research Funding to Institution. <br><b>ArriVent Biopharma<\/b> Independent Contractor, Other, Research Funding to Institution. <br><b>Teligene<\/b> Independent Contractor, Other, Research Funding to Institution. <br><b>Regeneron<\/b> Independent Contractor, Other, Research Funding to Institution. <br><b>Janssen<\/b> Independent Contractor, Travel, Other, Research Funding to Institution. <br><b>Boehringer Ingelheim<\/b> Independent Contractor, Other, Research Funding to Institution. <br><b>Spectrum Pharmaceutics<\/b> Independent Contractor, Travel. <br><b>Dizal<\/b> Other, Research Funding to Institution. <br><b>ThermoFisher<\/b> Other, Research Funding to Institution. <br><b>Takeda<\/b> Other, Research Funding to Institution. <br><b>AstraZeneca<\/b> Independent Contractor. <br><b>Novartis<\/b> Independent Contractor. <br><b>Hengrui Therapeutics<\/b> Independent Contractor. <br><b>Bayer<\/b> Independent Contractor. <br><b>Taiho<\/b> Independent Contractor. <br><b>Daiichi Sankyo<\/b> Independent Contractor. <br><b>Blueprint Medicines<\/b> Independent Contractor. <br><b>Sensei Biotherapeutics<\/b> Independent Contractor. <br><b>BlossomHill<\/b> Stock Option. <br><b>A. Spira, <\/b> <br><b>Array BioPharma<\/b> Independent Contractor. <br><b>Amgen<\/b> Independent Contractor, Other, Research Funding. <br><b>Novartis<\/b> Independent Contractor. <br><b>AstraZeneca\/MedImmune<\/b> Independent Contractor. <br><b>Mirati Therapeutics<\/b> Independent Contractor. <br><b>Gritstone Bio<\/b> Independent Contractor, Other, Research Funding. <br><b>Jazz Pharmaceuticals<\/b> Independent Contractor. <br><b>Merck<\/b> Independent Contractor. <br><b>Bristol-Myers Squibb<\/b> Independent Contractor, Other, Research Funding. <br><b>Takeda<\/b> Independent Contractor, Other, Research Funding. <br><b>Janssen Research & Development<\/b> Independent Contractor, Other, Research Funding. <br><b>Mersana<\/b> Independent Contractor. <br><b>Blueprint Medicines<\/b> Independent Contractor, Other, Research Funding. <br><b>Gritstone Bio<\/b> Independent Contractor. <br><b>Daiichi Sankyo<\/b> Independent Contractor, Other, Research Funding. <br><b>Regeneron<\/b> Independent Contractor, Other, Research Funding. <br><b>Eli Lilly<\/b> Independent Contractor, Stock. <br><b>Black Diamond Therapeutics<\/b> Independent Contractor, Other, Research Funding. <br><b>Sanofi<\/b> Independent Contractor. <br><b>AstraZeneca\/MedImmune<\/b> Other, Research Funding.<br><b>S. Gadgeel, <\/b> None..<br><b>Y. Yu, <\/b> None..<br><b>Y. Zhao, <\/b> None..<br><b>Y. Cheng, <\/b> None.&nbsp;<br><b>J. Riess, <\/b> <br><b>SeaGen<\/b> Independent Contractor. <br><b>Amgen<\/b> Independent Contractor. <br><b>Genentech<\/b> Independent Contractor. <br><b>Bristol Myers Squibb<\/b> Independent Contractor. <br><b>Regeneron<\/b> Independent Contractor. <br><b>Sanofi<\/b> Independent Contractor. <br><b>Daiichi Sankyo<\/b> Independent Contractor. <br><b>Beigene<\/b> Independent Contractor. <br><b>Merus NV<\/b> Independent Contractor. <br><b>Biodesix<\/b> Independent Contractor. <br><b>OncoCyte<\/b> Independent Contractor. <br><b>Janssen<\/b> Independent Contractor. <br><b>Bayer<\/b> Independent Contractor. <br><b>AstraZeneca<\/b> Other, Research Funding. <br><b>ArriVent<\/b> Other, Research Funding. <br><b>Summit<\/b> Other, Research Funding. <br><b>Novartis<\/b> Other, Research Funding. <br><b>Revolution Medicines<\/b> Other, Research Funding. <br><b>O. Juan-Vidal, <\/b> <br><b>Bristol-Myers Squibb<\/b> Independent Contractor. <br><b>Merck, Sharp, & Dohme<\/b> Independent Contractor, Travel. <br><b>Roche\/Genentech<\/b> Independent Contractor, Travel. <br><b>AstraZeneca<\/b> Independent Contractor, Travel. <br><b>Pfizer<\/b> Independent Contractor, Travel. <br><b>Eli Lilly<\/b> Independent Contractor. <br><b>Takeda<\/b> Independent Contractor, Travel. <br><b>Janssen<\/b> Independent Contractor.<br><b>B. Gao, <\/b> None.&nbsp;<br><b>K. Yoh, <\/b> <br><b>Abbvie<\/b> Grant\/Contract, Travel. <br><b>Amgen<\/b> Grant\/Contract, Travel. <br><b>ArriVent BioPharma<\/b> Grant\/Contract. <br><b>AstraZeneca<\/b> Grant\/Contract, Travel. <br><b>Boehringer Ingelheim<\/b> Independent Contractor, Grant\/Contract, Travel. <br><b>Chugai<\/b> Grant\/Contract, Travel. <br><b>Daiichi Sankyo<\/b> Grant\/Contract, Travel. <br><b>Eli Lilly<\/b> Grant\/Contract, Travel. <br><b>MSD<\/b> Grant\/Contract, Travel. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Taiho<\/b> Grant\/Contract, Travel. <br><b>Takeda<\/b> Grant\/Contract, Travel. <br><b>Bristol-Myer Squibb<\/b> Travel. <br><b>Kyowa Kirin<\/b> Travel. <br><b>Novartis<\/b> Travel. <br><b>Ono<\/b> Travel. <br><b>Otsuka<\/b> Travel. <br><b>M. Forster, <\/b> <br><b>Boehringer Ingelheim<\/b> Grant\/Contract. <br><b>MSD\/Merck<\/b> Independent Contractor, Grant\/Contract, Travel. <br><b>Amgen<\/b> Independent Contractor, Travel. <br><b>AstraZeneca<\/b> Independent Contractor, Travel. <br><b>Bayer<\/b> Independent Contractor, Travel. <br><b>Boxer<\/b> Independent Contractor, Travel. <br><b>Bristol-Myer Squibb<\/b> Independent Contractor, Travel. <br><b>Celgene<\/b> Independent Contractor, Travel. <br><b>Immutep<\/b> Independent Contractor, Travel. <br><b>Ixogen<\/b> Independent Contractor, Travel. <br><b>Janssen<\/b> Independent Contractor, Travel. <br><b>Oxford VacMedix<\/b> Independent Contractor, Travel. <br><b>Roche<\/b> Independent Contractor, Travel. <br><b>Takeda<\/b> Independent Contractor, Travel. <br><b>Transgene<\/b> Independent Contractor, Travel. <br><b>UltraHuman<\/b> Independent Contractor, Travel. <br><b>Oxford VacMedix<\/b> Independent Contractor, Travel. <br><b>EQRx<\/b> Independent Contractor, Travel. <br><b>S. Kitazono, <\/b> <br><b>AstraZeneca<\/b> Independent Contractor. <br><b>Bristol-Myer Squibb<\/b> Independent Contractor. <br><b>Chugai Pharma<\/b> Independent Contractor. <br><b>Ono Pharma<\/b> Independent Contractor.<br><b>H. Hayashi, <\/b> None.&nbsp;<br><b>D. Planchard, <\/b> <br><b>AstraZeneca<\/b> Independent Contractor, Grant\/Contract. <br><b>Bristol-Myer Squibb<\/b> Independent Contractor, Grant\/Contract. <br><b>Celgene<\/b> Independent Contractor, Grant\/Contract. <br><b>Eli Lilly<\/b> Independent Contractor, Grant\/Contract. <br><b>Merck<\/b> Independent Contractor, Grant\/Contract. <br><b>Novartis<\/b> Independent Contractor, Grant\/Contract. <br><b>Pfizer<\/b> Independent Contractor, Grant\/Contract. <br><b>prIME Oncology<\/b> Independent Contractor, Grant\/Contract. <br><b>Peer CME<\/b> Independent Contractor, Grant\/Contract. <br><b>Roche<\/b> Independent Contractor, Grant\/Contract. <br><b>Sanofi<\/b> Independent Contractor, Grant\/Contract. <br><b>Janssen<\/b> Independent Contractor, Grant\/Contract. <br><b>Abbvie<\/b> Independent Contractor, Grant\/Contract. <br><b>Daiichi Sankyo<\/b> Independent Contractor. <br><b>Y. Jiang, <\/b> <br><b>Allist Pharmaceuticals<\/b> Employment, Stock. <br><b>J. Huang, <\/b> <br><b>Arrivent BioPharma, Inc.<\/b> Employment, Stock. <br><b>N. Baio, <\/b> <br><b>Arrivent BioPharma, Inc.<\/b> Employment, Stock. <br><b>M. Kowanetz, <\/b> <br><b>Arrivent BioPharma, Inc.<\/b> Employment, Stock. <br><b>Bolt Biotherapeutics<\/b> Stock, Patent. <br><b>S. Wang, <\/b> <br><b>Arrivent BioPharma, Inc.<\/b> Employment, Stock. <br><b>W. Leung, <\/b> <br><b>Genentech<\/b> Stock Option. <br><b>Arrivent BioPharma, Inc.<\/b> Stock Option. <br><b>J. Y. Hsu, <\/b> <br><b>Arrivent BioPharma, Inc.<\/b> Employment, Stock.<br><b>J. Wang, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11619","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT152","PresenterBiography":null,"PresenterDisplayName":"Xiuning Le, MD;PhD","PresenterKey":"ea48d037-9246-4d75-adc0-0a9168bf63d2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT152. FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Lung cancer: non-small cell,PD-1,Dendritic cells,Immunotherapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>B. Liu<\/b><sup>1<\/sup>, A. Lisberg<sup>1<\/sup>, R. Salehi-Rad<sup>2<\/sup>, M. Oh<sup>1<\/sup>, J. M. Lee<sup>1<\/sup>, L. M. Tran<sup>1<\/sup>, K. Krysan<sup>1<\/sup>, R. J. Lim<sup>1<\/sup>, C. Dumitras<sup>1<\/sup>, Z. Jing<sup>1<\/sup>, F. Abtin<sup>1<\/sup>, R. D. Suh<sup>1<\/sup>, S. J. Genshaft<sup>1<\/sup>, S. S. Oh<sup>1<\/sup>, G. A. Fishbein<sup>1<\/sup>, A. Kaul<sup>1<\/sup>, K. S. Kahlon<sup>1<\/sup>, S. A. Ashouri<sup>1<\/sup>, J. W. Goldman<sup>1<\/sup>, D. A. Elashoff<sup>1<\/sup>, E. Garon<sup>1<\/sup>, S. M. Dubinett<sup>2<\/sup>; <br\/><sup>1<\/sup>UCLA David Geffen School of Medicine, Los Angeles, CA, <sup>2<\/sup>UCLA David Geffen School of Medicine & VA Greater Los Angeles Health Care Center, Los Angeles, CA","CSlideId":"","ControlKey":"fb5f77c8-0438-4899-a744-a529c02c35f9","ControlNumber":"10556","DisclosureBlock":"&nbsp;<b>B. Liu, <\/b> None.&nbsp;<br><b>A. Lisberg, <\/b> <br><b>Boston Scientific (an immediate family member)<\/b> Employment, Stock. <br><b>Daiichi Sankyo; Calithera Biosciences;  AstraZeneca; Dracen Pharmaceuticals; WindMIL; eFFECTOR Therapeutics; Duality Biologics<\/b> Grant\/Contract. <br><b>AstraZeneca; Bristol-Myers Squibb; Leica Biosystems; Jazz Pharmaceuticals; Novocure; Pfizer; MorphoSys; Eli-Lilly; Oncocyte<\/b> Other, Compensated Consultant\/Advisory Board. <br><b>Novartis; Regeneron; Janssen oncology; Sanofi group of companies; G1 Therapeutics; Molecular Axiom; Amgen; IQVIA; Bayer; Daiichi Sankyo<\/b> Other, Compensated Consultant\/Advisory Board.<br><b>R. Salehi-Rad, <\/b> None..<br><b>M. Oh, <\/b> None..<br><b>J. M. Lee, <\/b> None..<br><b>L. M. Tran, <\/b> None..<br><b>K. Krysan, <\/b> None..<br><b>R. J. Lim, <\/b> None..<br><b>C. Dumitras, <\/b> None..<br><b>Z. Jing, <\/b> None..<br><b>F. Abtin, <\/b> None..<br><b>R. D. Suh, <\/b> None..<br><b>S. J. Genshaft, <\/b> None..<br><b>S. S. Oh, <\/b> None..<br><b>G. A. Fishbein, <\/b> None..<br><b>A. Kaul, <\/b> None..<br><b>K. S. Kahlon, <\/b> None..<br><b>S. A. Ashouri, <\/b> None..<br><b>J. W. Goldman, <\/b> None..<br><b>D. A. Elashoff, <\/b> None.&nbsp;<br><b>E. Garon, <\/b> <br><b>Abbvie; Arcus; AstraZeneca, Atreca; BridgeBio; Bristol Myers Squibb; EMD Serono; Eli Lilly; Gilead<\/b> Other, Consultant and\/or Advisor. <br><b>GlaxoSmithKline; Hookipa; LianBio; Merck; Merus; Novartis; Nuvalent; Personalis; Regeneron<\/b> Other, Consultant and\/or Advisor. <br><b>Sanofi; Seagan; Sensei; Sumitomo; Summit; Synthekine; Xilio; Zymeworks<\/b> Other, Consultant and\/or Advisor. <br><b>ABL-Bio; Arrivent; AstraZeneca; Bristol Myers Squibb; Daiichi Sanko; Eli Lilly; EMD Serono; Genentech; Gilead<\/b> Grant\/Contract. <br><b>Iovance Biotherapeutics; Merck; Mirati Therapeutics; Novartis; Prelude; Regeneron; Synthekine<\/b> Grant\/Contract. <br><b>Daiichi-Sankyo; Ipsen<\/b> Other, Sponsored Independent Medical Education. <br><b>A2 Bio; Novartis<\/b> Travel. <br><b>S. M. Dubinett, <\/b> <br><b>EarlyDiagnostics; T-Cure Bioscience; LungLife AI; Johnson and Johnson Lung Cancer Initiative<\/b> Other, advisory board member. <br><b>Johnson and Johnson Lung Cancer Initiative; Novartis<\/b> Grant\/Contract.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11620","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT153","PresenterBiography":null,"PresenterDisplayName":"Bin Liu, PhD","PresenterKey":"ce57115a-4183-4346-bf53-6d35c42f3e48","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT153. Phase I trial of intratumoral administration of autologous <i>CCL21 <\/i>gene-modified dendritic cells in combination with pembrolizumab for advanced NSCLC: Feasibility of repeated IT injections","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase I trial of intratumoral administration of autologous <i>CCL21 <\/i>gene-modified dendritic cells in combination with pembrolizumab for advanced NSCLC: Feasibility of repeated IT injections","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"NSCLC,Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI),EGFR TKI resistance,C797S mutation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Lim<\/b><sup>1<\/sup>, B. Cho<sup>2<\/sup>, J. Han<sup>3<\/sup>, S. Kim<sup>4<\/sup>, K. Lee<sup>5<\/sup>, M. Nagasaka<sup>6<\/sup>, A. Jo<sup>7<\/sup>, E. Seah<sup>7<\/sup>, C. Kim<sup>7<\/sup>, T. Reungwetwattana<sup>8<\/sup>; <br\/><sup>1<\/sup>Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of, <sup>2<\/sup>Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of, <sup>3<\/sup>Center for Lung Cancer, National Cancer Center - Graduate School of Cancer Science and Policy, Goyang, Korea, Republic of, <sup>4<\/sup>Division of Medical Oncology, Asan Medical Center, University of Ulsan, Seoul, Korea, Republic of, <sup>5<\/sup>Division of Medical Oncology, Chungbuk National University Hospital, Cheongju, Korea, Republic of, <sup>6<\/sup>Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Healthcare, California, CA, <sup>7<\/sup>J INTS BIO Inc, Seoul, Korea, Republic of, <sup>8<\/sup>Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand","CSlideId":"","ControlKey":"0c639925-038b-4f8b-a660-735edf92ac7c","ControlNumber":"9860","DisclosureBlock":"<b>&nbsp;S. Lim, <\/b> <br><b>Yuhan Pharmaceuticals; Janssen<\/b> Grant\/Contract. <br><b>B. Cho, <\/b> <br><b>MOGAM Institute; LG Chem; Oscotec; Interpark Bio Convergence Corp; GIInnovation; GI-Cell; Abion; Abbvie; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Champions Onoclogy<\/b> Grant\/Contract. <br><b>CJ bioscience; CJ Blossom Park; Cyrus; Dizal Pharma; Genexine; Janssen; Lilly; MSD; Novartis; Nuvalent; Oncternal; Ono; Regeneron; Dong-A ST; Bridgebio therapeutics; Yuhan; ImmuneOncia; Illumina<\/b> Grant\/Contract. <br><b>Kanaph therapeutics; Therapex; JINTSbio; Hanmi; CHA Bundang Medical Center; Vertical Bio AG<\/b> Grant\/Contract. <br><b>Champions Oncology; Crown Bioscience; Imagen; PearlRiver Bio GmbH<\/b> Other, Royalties\u000d\u000a(PDX, PDO, PDC Licensing Contract – not patent). <br><b>Abion; BeiGene; Novartis; AstraZeneca; Boehringer-Ingelheim; Roche; BMS; CJ; CureLogen; Cyrus therapeutics; Ono; Onegene Biotechnology; Yuhan; Pfizer; Eli Lilly; GI-Cell<\/b> Other, Consultant. <br><b>Guardant; HK Inno-N; Imnewrun Biosciences Inc.;  Janssen; Takeda; MSD; Janssen; Medpacto; Blueprint medicines; RandBio; Hanmi<\/b> Other, Consultant. <br><b>Yonsei University Health System<\/b> Employment. <br><b>KANAPH Therapeutic Inc; Bridgebio therapeutics; Cyrus therapeutics; Guardant Health; Oscotec Inc; J INTS Bio; Therapex Co., Ltd; Gliead; Amgen<\/b> Other, Advisory board. <br><b>TheraCanVac Inc; Gencurix Inc; Bridgebio therapeutics; KANAPH Therapeutic Inc; Cyrus therapeutics; Interpark Bio Convergence Corp.; J INTS BIO<\/b> Stock. <br><b>J INTS BIO<\/b> Other, Member of the board of directors. <br><b>DAAN Biotherapeutics<\/b> Other, Founder. <br><b>J. Han, <\/b> <br><b>Pfizer; ONO; Roche; Takeda<\/b> Grant\/Contract. <br><b>Astra Zeneca; Jassen; Norvatis; Amgen; Oncobix; Takeda; Merck; Pfizer; BMS;<\/b> Independent Contractor. <br><b>Astra Zeneca<\/b> Other, Payment for expert testimony. <br><b>Jassen; Astra Zeneca<\/b> Other, Participation on a Data \u000d\u000aSafety Monitoring Board or Advisory Board \u000d\u000a. <br><b>Astra Zeneca; Jassen; Merck; Norvatis; Roche; Takeda; Yuhan; Pfizer<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events.<br><b>S. Kim, <\/b> None..<br><b>K. Lee, <\/b> None.&nbsp;<br><b>M. Nagasaka, <\/b> <br><b>AstraZeneca; Daiichi Sankyo; Novartis; EMD Serono; Pfizer; Lilly; Genentech; Regeneron; BMS<\/b> Other, Advisory boards. <br><b>Caris Life Sciences; Takeda; Janssen; Blueprint Medicines; Mirati<\/b> Grant\/Contract. <br><b>AnHeart Therapeutics<\/b> Travel.<br><b>A. Jo, <\/b> None..<br><b>E. Seah, <\/b> None..<br><b>C. Kim, <\/b> None.&nbsp;<br><b>T. Reungwetwattana, <\/b> <br><b>Astrazeneca; Boehringer-Ingelheim; Roche; Novartis; MSD; Bristol Myers Squibb; Amgen; Pfizer; Yuhan; J & J<\/b> Other, Advisory board. <br><b>Astrazeneca; Boehringer-Ingelheim; Roche; Novartis; MSD; Yuhan<\/b> Other, Clinical Research. <br><b>Astrazeneca; Boehringer-Ingelheim; Roche; Novartis; MSD; Bristol Myers Squibb; Amgen; Pfizer<\/b> Other, Speaker.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11621","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT154","PresenterBiography":"","PresenterDisplayName":"Sun Min Lim, MD;PhD","PresenterKey":"9c00099e-28f8-4e0e-87af-b91bf6958fc6","PresenterPhoto":"https:\/\/files.abstractsonline.com\/assocphotos\/101\/9c00099e-28f8-4e0e-87af-b91bf6958fc6.profile.jpg","SearchResultActions":null,"SearchResultBody":"CT154. Phase 1\/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI, in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced\/metastatic non-small cell lung cancer (NSCLC)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1\/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI, in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced\/metastatic non-small cell lung cancer (NSCLC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Cancer therapy,Targeted therapy,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"A. Dowlati<sup>1<\/sup>, A. Spira<sup>2<\/sup>, <b>X. Shen<\/b><sup>3<\/sup>, Y. Fu<sup>4<\/sup>, Y. Pan<sup>4<\/sup>, L. Liu<sup>3<\/sup>, R. Zhou<sup>3<\/sup>, Y.-L. Wu<sup>5<\/sup>; <br\/><sup>1<\/sup>University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, <sup>2<\/sup>NEXT Oncology Virginia, Fairfax, VA, <sup>3<\/sup>Zai Lab (US) LLC, Cambridge, MA, <sup>4<\/sup>Zai Lab (Shanghai), Co. Ltd, Shanghai, China, <sup>5<\/sup>Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China","CSlideId":"","ControlKey":"0d89c22f-fdad-4eb9-ade3-4d5fab2694e0","ControlNumber":"9866","DisclosureBlock":"<b>&nbsp;A. Dowlati, <\/b> <br><b>Amgen<\/b> Other, Advisory Board. <br><b>Jazz<\/b> Other, Advisory Board. <br><b>Prelude<\/b> Other, Advisory Board. <br><b>Seagen<\/b> Other, Advisory Board. <br><b>Puma<\/b> Other, Advisory Board. <br><b>AstraZeneca<\/b> Other, Advisory Board.<br><b>A. Spira, <\/b> None.&nbsp;<br><b>X. Shen, <\/b> <br><b>Zai Lab<\/b> Employment, Stock, Stock Option. <br><b>Y. Fu, <\/b> <br><b>Zai Lab<\/b> Employment, Stock, Stock Option. <br><b>Y. Pan, <\/b> <br><b>Zai Lab<\/b> Employment, Stock, Stock Option. <br><b>L. Liu, <\/b> <br><b>Zai Lab<\/b> Employment, Stock, Stock Option. <br><b>R. Zhou, <\/b> <br><b>Zai Lab<\/b> Employment, Stock, Stock Option.<br><b>Y. Wu, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11622","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT155","PresenterBiography":"","PresenterDisplayName":"Xiaodong Shen, MD;PhD","PresenterKey":"41a72c4b-1f11-4453-85e5-4a516cdd7695","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT155. Trial in progress: A phase Ia\/Ib, an open-label, multicenter study of ZL-1310 to evaluate the safety, tolerability, and pharmacokinetics in subjects with small cell lung cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Trial in progress: A phase Ia\/Ib, an open-label, multicenter study of ZL-1310 to evaluate the safety, tolerability, and pharmacokinetics in subjects with small cell lung cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"BTK,B cells,Lymphoma,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Woyach<\/b><sup>1<\/sup>, M. Tees<sup>2<\/sup>, N. Mota<sup>3<\/sup>, G. Brown<sup>3<\/sup>, S. Kim<sup>3<\/sup>, M. R. Patel<sup>4<\/sup>; <br\/><sup>1<\/sup>Ohio State University, Columbus, OH, <sup>2<\/sup>Colorado Blood Cancer Institute, Denver, CO, <sup>3<\/sup>Accutar Biotechnology Inc., Cranbury, NJ, <sup>4<\/sup>Florida Cancer Specialists\/Sarah Cannon Research Institute, Sarasota, FL","CSlideId":"","ControlKey":"431eb5ca-a0ca-4a86-9a37-59a850f8a444","ControlNumber":"10303","DisclosureBlock":"<b>&nbsp;J. Woyach, <\/b> <br><b>Abbvie, Janssen, Pharmacyclics, Morphosys, Schrodinger<\/b> Other, Research funding. <br><b>Abbvie, AstraZeneca, Beigene, Genentech, Loxo\/Lilly, Merck, Newave, Pharmacyclics<\/b> Other, Consulting.<br><b>M. Tees, <\/b> None.&nbsp;<br><b>N. Mota, <\/b> <br><b>Accutar Biotechnology Inc.<\/b> Employment. <br><b>G. Brown, <\/b> <br><b>Accutar Biotechnology Inc.<\/b> Employment. <br><b>S. Kim, <\/b> <br><b>Accutar Biotechnology Inc.<\/b> Employment. <br><b>M. R. Patel, <\/b> <br><b>ION Pharma<\/b> Other, Leadership. <br><b>Janssen Oncology<\/b> Other, Honoraria. <br><b>Accutar Biotechnology Inc., Daiichi Sankyo, Nurix, Olema Pharmaceuticals<\/b> Other, Consulting or Advisory Role. <br><b>Accutar Biotechnology Inc., Acerta Pharma, Adagene, ADC Therapeutics, Agenus, Aileron Therapeutics, Artios, Astellas, AstraZeneca, BioNTech AG, Boehringer Ingelheim, Black Diamond Therapeutics<\/b> Other, Research Funding to Institution. <br><b>Blueprint Pharmaceuticals, Bayer, Bicycle Therapeutics, BioTheryX, Compugen, Cullinan Oncology, Celgene, CicloMed, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo, Lilly, Erasca, Inc.<\/b> Other, Research Funding to Institution. <br><b>Evelo Therapeutics, Genentech\/Roche, Gilead Sciences, GlaxoSmithKline, H3 Biomedicine, Hengrui Therapeutics, Hutchison MediPharma, IgM Biosciences, Immunogen, Immune-Onc Therapeutics, Immunitas<\/b> Other, Research Funding to Institution. <br><b>Jazz Pharmaceuticals, Jacobio, Janssen, Klus Pharma, Kymab, Loxo, LSK Biopartners, Lycera, Mabspace, Macrogenics, Merck, Millennium, Mirati Therapeutics, Moderna Therapeutics, NGM Biopharmaceuticals<\/b> Other, Research Funding to Institution. <br><b>Novartis, Nurix, Olema, ORIC Pharmaceuticals, Pionyr, PureTech, Pfizer, Prelude Therapeutics,  Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Step Pharma, Samumed, Silicon Therapeutics<\/b> Other, Research Funding to Institution. <br><b>Seven and Eight Biopharmaceuticals, Syndax, Synthorx, Taiho Pharmaceutical, Tesaro, TopAlliance BioSciences Inc, Treadwell, TeneoBio, Treadwell Therapeutics, Xencor, Vigeo, Zymeworks<\/b> Other, Research Funding to Institution.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11623","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT156","PresenterBiography":null,"PresenterDisplayName":"Jennifer Woyach, MD","PresenterKey":"ab3df617-9880-4b84-b5a2-1147ac580403","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT156. A Phase I study evaluating AC676, an innovative BTK chimeric degrader, in patients with relapsed and refractory B-cell malignancies","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A Phase I study evaluating AC676, an innovative BTK chimeric degrader, in patients with relapsed and refractory B-cell malignancies","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Melanoma\/skin cancers,Brain metastasis,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>M. Seetharam<\/b><sup>1<\/sup>, R. Dronca<sup>2<\/sup>, A. Z. Dudek<sup>3<\/sup>, G. Nelson<sup>2<\/sup>, M. Block<sup>3<\/sup>, S. Starling<sup>2<\/sup>, A. Baskin<sup>2<\/sup>, R. Bradshaw<sup>3<\/sup>, C. Nelson<sup>1<\/sup>, K. Andrews<sup>1<\/sup>, A. Birgin<sup>3<\/sup>, C. Watson<sup>2<\/sup>, Y. Yan<sup>2<\/sup>, D. Mahadevan<sup>4<\/sup>, S. Markovic<sup>3<\/sup>, T. Myers<sup>5<\/sup>, L. Paradiso<sup>5<\/sup>, H. Babiker<sup>2<\/sup>; <br\/><sup>1<\/sup>Mayo Clinic Cancer Center, Phoenix, AZ, <sup>2<\/sup>Mayo Clinic Cancer Center, Jacksonville, FL, <sup>3<\/sup>Mayo Clinic Cancer Center, Rochester, MN, <sup>4<\/sup>University of Texas Health, San Antonio, AZ, <sup>5<\/sup>Spirita Oncology, Natick, MA","CSlideId":"","ControlKey":"f63ed561-3574-4b50-aee8-3ffca0e3fe1b","ControlNumber":"10580","DisclosureBlock":"&nbsp;<b>M. Seetharam, <\/b> None..<br><b>R. Dronca, <\/b> None..<br><b>A. Z. Dudek, <\/b> None..<br><b>G. Nelson, <\/b> None..<br><b>M. Block, <\/b> None..<br><b>S. Starling, <\/b> None..<br><b>A. Baskin, <\/b> None..<br><b>R. Bradshaw, <\/b> None..<br><b>C. Nelson, <\/b> None..<br><b>K. Andrews, <\/b> None..<br><b>A. Birgin, <\/b> None..<br><b>C. Watson, <\/b> None..<br><b>Y. Yan, <\/b> None..<br><b>D. Mahadevan, <\/b> None..<br><b>S. Markovic, <\/b> None.&nbsp;<br><b>T. Myers, <\/b> <br><b>Spirita Oncology<\/b> Employment. <br><b>L. Paradiso, <\/b> <br><b>Spirita Oncology<\/b> Employment.<br><b>H. Babiker, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11624","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT157","PresenterBiography":null,"PresenterDisplayName":"Mahesh Seetharam, MBBS;MD","PresenterKey":"b18397c4-5295-415c-93b2-fbb54f743d1d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT157. Phase 1 trial of MEK1 inhibitor E6201 plus dabrafenib in patients (pts) with <i>BRAF V600<\/i>-mutated metastatic melanoma (MM) with central nervous system (CNS) metastases (mets)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1 trial of MEK1 inhibitor E6201 plus dabrafenib in patients (pts) with <i>BRAF V600<\/i>-mutated metastatic melanoma (MM) with central nervous system (CNS) metastases (mets)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"CDK inhibitor,Transcriptional repression,Targeted therapy,Myc,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>M. Villalona Calero<\/b><sup>1<\/sup>, M. Agulnik<sup>1<\/sup>, M. Mita<sup>2<\/sup>, A. Mita<sup>2<\/sup>, N. Federman<sup>3<\/sup>, D. Rasco<sup>4<\/sup>, D. Spigel<sup>5<\/sup>, J. Luo<sup>6<\/sup>, G. Hanna<sup>6<\/sup>, G. Cote<sup>7<\/sup>, M. A. Salkeni<sup>8<\/sup>, R. Chugh<sup>9<\/sup>, N. R. Ammakkanavar<sup>10<\/sup>, S. A. Shah<sup>11<\/sup>, A. Rao<sup>12<\/sup>, K. Kumar Sankhala<sup>13<\/sup>, R. E. Cutler<sup>14<\/sup>, T. Hood<sup>14<\/sup>, L. Carvajal<sup>14<\/sup>, C. MacKenzie<sup>14<\/sup>, C. Lin<sup>14<\/sup>, J. DiMartino<sup>14<\/sup>, E. A. Olek<sup>14<\/sup>, B. Van Tine<sup>15<\/sup>; <br\/><sup>1<\/sup>City of Hope National Medical Center, Duarte, CA, <sup>2<\/sup>Cedars-Sinai Cancer Institute, Los Angeles, CA, <sup>3<\/sup>UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, <sup>4<\/sup>START, San Antonio, TX, <sup>5<\/sup>Sarah Cannon Research Institute at Tennessee Oncology PLLC, Nashville, TN, <sup>6<\/sup>Dana Farber Cancer Institute, Boston, MA, <sup>7<\/sup>Massachusetts General Hospital, Boston, MA, <sup>8<\/sup>Virginia Cancer Specialists, Fairfax, VA, <sup>9<\/sup>University of Michigan Cancer Center, Ann Arbor, MI, <sup>10<\/sup>Community Cancer Center North, Indianapolis, IN, <sup>11<\/sup>Pennsylvania Cancer Specialists and Research Institute, Gettysburg, PA, <sup>12<\/sup>Memorial Care Fountain Valley, Fountain Valley, CA, <sup>13<\/sup>NextGen Oncology, Los Angeles, CA, <sup>14<\/sup>Kronos Bio, San Mateo, CA, <sup>15<\/sup>Washington Universtiy in St. Louis, St. Louis, MO","CSlideId":"","ControlKey":"0240d480-4bd6-4c1a-add3-a2c588291897","ControlNumber":"9749","DisclosureBlock":"<b>&nbsp;M. Villalona Calero, <\/b> <br><b>Kronos Bio<\/b> Other, Clinical Study investigator. <br><b>M. Agulnik, <\/b> <br><b>Kronos Bio<\/b> Other, Sub-investigator on clinical trial. <br><b>M. Mita, <\/b> <br><b>Kronos Bio<\/b> Other, Principal study investigator. <br><b>A. Mita, <\/b> <br><b>Kronos Bio<\/b> Other, Principal investigator on study. <br><b>N. Federman, <\/b> <br><b>Kronos Bio<\/b> Other, Principal study investigator. <br><b>D. Rasco, <\/b> <br><b>Kronos Bio<\/b> Other, Principal investigator on Study. <br><b>D. Spigel, <\/b> <br><b>Kronos Bio<\/b> Other, Principal investigator on Study. <br><b>J. Luo, <\/b> <br><b>Kronos Bio<\/b> Other, Principal study investigator. <br><b>G. Hanna, <\/b> <br><b>Kronos Bio<\/b> Other, Principal study investigator. <br><b>G. Cote, <\/b> <br><b>Kronos Bio<\/b> Other, Principal Study Investigator. <br><b>M. A. Salkeni, <\/b> <br><b>Kronos Bio<\/b> Other, Principal investigator on study. <br><b>R. Chugh, <\/b> <br><b>Kronos Bio<\/b> Other, Principal investigator on study. <br><b>N. R. Ammakkanavar, <\/b> <br><b>Kronos Bio<\/b> Other, Study Principal investigator. <br><b>S. A. Shah, <\/b> <br><b>Kronos Bio<\/b> Other, Study Principal investigator. <br><b>A. Rao, <\/b> <br><b>Kronos Bio<\/b> Study Principal Investigator. <br><b>K. Kumar Sankhala, <\/b> <br><b>Kronos Bio<\/b> Other, Study Principal Investigator. <br><b>R. E. Cutler, <\/b> <br><b>Kronos Bio<\/b> Employment, Stock, Stock Option. <br><b>T. Hood, <\/b> <br><b>Kronos Bio<\/b> Employment, Stock, Stock Option. <br><b>L. Carvajal, <\/b> <br><b>Kronos Bio<\/b> Employment, Stock, Stock Option. <br><b>C. MacKenzie, <\/b> <br><b>Kronos Bio<\/b> Employment, Stock, Stock Option. <br><b>C. Lin, <\/b> <br><b>Kronos Bio<\/b> Employment, Stock, Stock Option. <br><b>J. DiMartino, <\/b> <br><b>Kronos Bio<\/b> Stock, Stock Option. <br><b>E. A. Olek, <\/b> <br><b>Kronos Bio<\/b> Employment, Stock, Stock Option. <br><b>B. Van Tine, <\/b> <br><b>Kronos Bio<\/b> Other, Study Principal Investigator.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11625","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT158","PresenterBiography":null,"PresenterDisplayName":"Miguel Villalona Calero, MD","PresenterKey":"68bf3c63-ae3b-45d0-b353-0a769c0d7287","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT158. A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed, refractory and transcriptionally addicted solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed, refractory and transcriptionally addicted solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Phase I,Antibody-drug conjugate (ADC),,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"A. A. Davis<sup>1<\/sup>, E. E. Dumbrava<sup>2<\/sup>, A. Kalyan<sup>3<\/sup>, N. V. Uboha<sup>4<\/sup>, H. S. Mahdi<sup>5<\/sup>, R. A. Patel<sup>6<\/sup>, F. Dayyani<sup>7<\/sup>, J. Porzel<sup>1<\/sup>, W. L. Hensing<sup>8<\/sup>, C. X. Ma<sup>1<\/sup>, R. Bose<sup>1<\/sup>, <b>H. Park<\/b><sup>9<\/sup>; <br\/><sup>1<\/sup>Washington University School of Medicine in St. Louis, St. Louis, MO, <sup>2<\/sup>MD Anderson Cancer Center, Houston, TX, <sup>3<\/sup>Northwestern University, Chicago, IL, <sup>4<\/sup>University of Wisconsin Madison, Madison, WI, <sup>5<\/sup>University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>6<\/sup>University of Kentucky, Lexington, KY, <sup>7<\/sup>University of California, Irvine, Irvine, CA, <sup>8<\/sup>Saint Luke’s Cancer Institute, Kansas City, MO, <sup>9<\/sup>Dana Farber Cancer Institute, Boston, MA","CSlideId":"","ControlKey":"8395317f-d726-455c-91c2-75f260b71e2f","ControlNumber":"9785","DisclosureBlock":"<b>&nbsp;A. A. Davis, <\/b> <br><b>Pfizer, Inc<\/b> Other, Advisory board. <br><b>Biotheranostics<\/b> Other, Advisory board. <br><b>E. E. Dumbrava, <\/b> <br><b>Bayer HealthCare Pharmaceuticals Inc; Immunocore LTD; Amgen; Aileron Therapeutics; Compugen Ltd; TRACON Pharmaceuticals Inc; Unum Therapeutics; Gilead Immunomedics<\/b> Other, Research or grant funding. <br><b>BOLT Therapeutics; Aprea Therapeutics; Bellicum Pharmaceuticals; PMV Pharma; Triumvira Immunologics; Seagen Inc; Mereo BioPharma 5 Inc; Sanofi<\/b> Other, Research or grant funding. <br><b>Rain Oncology; Astex Therapeutics; Sotio; Poseida;  Mersana Therapeutics; Genentech; Boehringer Ingelheim; Dragonfly Therapeutics; A2A Pharmaceuticals<\/b> Other, Research or grant funding. <br><b>BOLT Therapeutics; Mersana Therapeutics; Orum Therapeutics; Summit Therapeutics; Fate Therapeutics; PMV Pharma<\/b> Other, Advisory board. <br><b>PMV Pharma<\/b> Other, Speaker. <br><b>ASCO; LFSA Association; Rain Oncology; Banner MD Anderson Cancer Center; Triumvira Immunologics<\/b> Other, Travel, accommodations, expenses.<br><b>A. Kalyan, <\/b> None..<br><b>N. V. Uboha, <\/b> None..<br><b>H. S. Mahdi, <\/b> None..<br><b>R. A. Patel, <\/b> None.&nbsp;<br><b>F. Dayyani, <\/b> <br><b>Astellas; Astrazeneca; Eisai; Exelixis; Ipsen; Servier; Sirtex; Takeda.<\/b> Other, Honoraria. <br><b>Amgen, Astellas, Astrazeneca; Bayer; Eisai; Exelixis; Ipsen; Roche; Signatera.<\/b> Other, Research grant to institution.<br><b>J. Porzel, <\/b> None.&nbsp;<br><b>W. L. Hensing, <\/b> <br><b>Gilead<\/b> Other, Advisory board. <br><b>C. X. Ma, <\/b> <br><b>Novartis; AstraZeneca; Regor Therapeutics; Biovica; Olaris; Gilead; Pfizer; Lilly;  Diaiichi; Stemline; Tersera<\/b> Other, Consulting. <br><b>Pfizer; Puma<\/b> Other, Research funding. <br><b>R. Bose, <\/b> <br><b>Genentech<\/b> Other, Consulting. <br><b>Puma Biotechnology<\/b> Other, Research grant (institutional). <br><b>H. Park, <\/b> <br><b>Ambrx; Amgen; Aprea Therapeutics; AstraZenea; Bayer; BeiGene; BJ Bioscience; Bolt Biotherapuetics; Bristol-Myers Squibb; Daiichi Sankyo; Exelixis; Genetech; GlaxoSmithKline; Goassamer Bio<\/b> Other, Institutional research grants. <br><b>ImmuneOncia; Immunomedics; Incyte; Jounce Therapuetics; Lilly; MabSpace Biosciences; Macrogenics; Merck; Mersana; Mirati Therapuetics; Novartis; Oncologie; Pfizer; PsiOxus Therapeutics<\/b> Other, Institutional research grants. <br><b>Puma Biotechnology; Regeneron; Seagen; Strata Oncology; Synermore Biologics; Tizona Therapuetics Inc.; Top Alliance BioScience; Turning Point Therapeutics; Vedanta Biosciences<\/b> Other, Institutional research grants.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11626","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT159","PresenterBiography":null,"PresenterDisplayName":"Haeseong Park, MD;MPH","PresenterKey":"8ba995b7-708a-4c42-a071-0455fc9934a4","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT159. Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"CAR T cells,Adoptive cell therapy,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Choo<\/b><sup>1<\/sup>, W. Tan<sup>2<\/sup>, L. Luk<sup>2<\/sup>, J. Zeng<sup>2<\/sup>, T. Soh<sup>3<\/sup>, S. Soon<sup>1<\/sup>, J. Lieow<sup>1<\/sup>, C. Wong<sup>1<\/sup>, M. Pang<sup>1<\/sup>, S. Bari<sup>4<\/sup>, M. Poon<sup>1<\/sup>, L. Koh<sup>1<\/sup>, W. Chng<sup>1<\/sup>, A. Jeyasekharan<sup>1<\/sup>, L. Tan<sup>1<\/sup>, E. Chan<sup>1<\/sup>, R. Sundar<sup>1<\/sup>; <br\/><sup>1<\/sup>National University Cancer Institute Singapore, Singapore, Singapore, <sup>2<\/sup>CytoMed Therapeutics Limited, Singapore, Singapore, <sup>3<\/sup>National University Hospital Singapore, Singapore, Singapore, <sup>4<\/sup>Advanced Cell Therapy & Research Institute, Singapore, Singapore, Singapore","CSlideId":"","ControlKey":"7887d86a-1f68-4835-9b2b-8a26ca6a7d5d","ControlNumber":"9845","DisclosureBlock":"&nbsp;<b>J. Choo, <\/b> None.&nbsp;<br><b>W. Tan, <\/b> <br><b>CytoMed Therapeutics Limited<\/b> Employment. <br><b>L. Luk, <\/b> <br><b>CytoMed Therapeutics Limited<\/b> Employment. <br><b>J. Zeng, <\/b> <br><b>CytoMed Therapeutics Limited<\/b> Employment.<br><b>T. Soh, <\/b> None..<br><b>S. Soon, <\/b> None..<br><b>J. Lieow, <\/b> None..<br><b>C. Wong, <\/b> None..<br><b>M. Pang, <\/b> None..<br><b>S. Bari, <\/b> None..<br><b>M. Poon, <\/b> None..<br><b>L. Koh, <\/b> None..<br><b>W. Chng, <\/b> None..<br><b>A. Jeyasekharan, <\/b> None..<br><b>L. Tan, <\/b> None..<br><b>E. Chan, <\/b> None.&nbsp;<br><b>R. Sundar, <\/b> <br><b>Bristol Myers Squibb<\/b> Other, Honoraria, advisory board. <br><b>MSD<\/b> Travel, Other, Honoraria, consulting fees, research funding. <br><b>Lilly<\/b> Other, Honoraria. <br><b>Roche<\/b> Travel, Other, Honoraria. <br><b>Taiho Pharmaceutical<\/b> Travel, Other, Honoraria, consulting fees. <br><b>AstraZeneca<\/b> Travel, Other, Honoraria, advisory board. <br><b>Paxman Coolers<\/b> Patent, Other, Research funding. <br><b>CytoMed Therapeutics Limited<\/b> Travel. <br><b>Eisai<\/b> Travel, Other, Advisory board, consulting fees. <br><b>Bayer<\/b> Other, Advisory Board. <br><b>Novartis<\/b> Other, Advisory board. <br><b>Glaxosmithkline<\/b> Other, Advisory Board. <br><b>Astellas<\/b> Other, Advisory board. <br><b>Ipsen<\/b> Other, Advisory Board. <br><b>Natera<\/b> Other, research funding. <br><b>Auristone<\/b> Patent.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11627","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT160","PresenterBiography":null,"PresenterDisplayName":"Joan Choo","PresenterKey":"73acb212-bb46-440a-b5a8-35cef393bbff","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT160. A phase I trial to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted &#947;&#948; T cells in subjects with advanced solid tumors or hematological malignancies (the ANGELICA Trial)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase I trial to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted &#947;&#948; T cells in subjects with advanced solid tumors or hematological malignancies (the ANGELICA Trial)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Immuno-oncology,Innate immunity,Safety,Targeted therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. S. Weston<\/b><sup>1<\/sup>, T. Thode<sup>1<\/sup>, M. Shah<sup>2<\/sup>, A. Seiz<sup>2<\/sup>, J. Northrup<sup>2<\/sup>, S. Kasibhatla<sup>1<\/sup>, M. Kaadige<sup>1<\/sup>, S. Sharma<sup>1<\/sup>; <br\/><sup>1<\/sup>TGen (The Translational Genomics Research Institute), Phoenix, AZ, <sup>2<\/sup>Stingray Therapeutics, Houston, TX","CSlideId":"","ControlKey":"36679b09-c0f8-46c6-8bdc-04565393e0a4","ControlNumber":"10845","DisclosureBlock":"<b>&nbsp;A. S. Weston, <\/b> <br><b>Stingray Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>T. Thode, <\/b> <br><b>Stingray Therapeutics<\/b> Independent Contractor, Stock, Stock Option. <br><b>M. Shah, <\/b> <br><b>Stingray Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>A. Seiz, <\/b> <br><b>Stingray Therapeutics<\/b> Stock Option. <br><b>J. Northrup, <\/b> <br><b>Stingray Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>S. Kasibhatla, <\/b> <br><b>Stingray Therapeutics<\/b> Stock, Stock Option. <br><b>M. Kaadige, <\/b> <br><b>Stingray Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>S. Sharma, <\/b> <br><b>Stingray Therapeutics<\/b> Stock, Stock Option.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11628","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT161","PresenterBiography":null,"PresenterDisplayName":"Alexis Weston, BS","PresenterKey":"5be9ce4a-6dd9-4421-866a-7e3a2cce7cbc","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT161. First-in-human study of ENPP1 inhibitor, SR-8541A, for the treatment of solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First-in-human study of ENPP1 inhibitor, SR-8541A, for the treatment of solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Immuno-oncology,CCR 8,Cancer progression,Checkpoint Inhibitor Resistance ,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"E. Garralda<sup>1<\/sup>, V. Boni<sup>2<\/sup>, D. Vincente Baz<sup>3<\/sup>, A. Chaudhry<sup>4<\/sup>, I. Gil Bazo<sup>5<\/sup>, M. Gutierrez<sup>6<\/sup>, J. Malhotra<sup>7<\/sup>, C. Guzman Alonso<sup>8<\/sup>, V. Gambardella<sup>9<\/sup>, M. Chisamore<sup>10<\/sup>, R. Zhou<sup>11<\/sup>, <b>M. Tea<\/b><sup>12<\/sup>, D. Doroshow<sup>13<\/sup>; <br\/><sup>1<\/sup>Hospital&#8239;Universitario&#8239;Vall d'Hebron, Early Clinical Drug Development, Barcelona, Spain, <sup>2<\/sup>NEXT Madrid, Hospital Universitario Quironsalud, Madrid, Spain, <sup>3<\/sup>Hospital Universitario Virgen Macarena, Medical Oncology, Seville, Spain, <sup>4<\/sup>Summit Cancer Centers, Internal Medicine, Medical Oncology, Spokane, WA, <sup>5<\/sup>Fundacion Instituto Valenciano de Oncologia, Department of Oncology; CIBERONIC, Valencia, Spain, <sup>6<\/sup>John Theurer Cancer Center at Hackensack University Medical Center, Drug Discovery, Phase 1 Program, Hackensack, NJ, <sup>7<\/sup>City of Hope National Medical Center, Medical Oncology & Therapeutics Research, Duarte, CA, <sup>8<\/sup>NEXT Barcelona, IOB-Hospital Quironsalud Barcelona, Barcelona, Spain, <sup>9<\/sup>Hospital Clinico Universitario de Valencia, Valencia, Spain, <sup>10<\/sup>Merck & Co., Inc., Rahway, NJ, <sup>11<\/sup>Zai Lab (US) LLC, Cambridge, MA, <sup>12<\/sup>Zai Lab US, Cambridge, MA, <sup>13<\/sup>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY","CSlideId":"","ControlKey":"61db69df-bae0-413f-af8a-b4e43f35794c","ControlNumber":"9592","DisclosureBlock":"<b>&nbsp;E. Garralda, <\/b> <br><b>Novartis<\/b> Grant\/Contract, Other, Speaker fee. <br><b>Roche<\/b> Grant\/Contract, Other, Speaker fee. <br><b>Thermo Fisher<\/b> Grant\/Contract, Other, Consulting fees, Speaker fee. <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Taiho<\/b> Grant\/Contract. <br><b>BeiGene<\/b> Grant\/Contract. <br><b>Janssen<\/b> Grant\/Contract. <br><b>Roche<\/b> Other, Consulting fees. <br><b>Ellipses Pharma<\/b> Other, Consulting fees. <br><b>Boehringer Ingelheim<\/b> Other, Consulting fees. <br><b>Janssen Global Services<\/b> Other, Consulting fees. <br><b>Seattle Genetics<\/b> Other, Consulting fees. <br><b>MabDiscovery<\/b> Other, Consulting fees. <br><b>Anaveon<\/b> Other, Consulting fees. <br><b>F-Star Therapeutics<\/b> Other, Consulting fees. <br><b>Hengrui<\/b> Other, Consulting fees. <br><b>Sanofi<\/b> Other, Consulting fees. <br><b>Incyte<\/b> Other, Consulting fees. <br><b>Medscape; Speaker fee<\/b> Other, Consulting fees. <br><b>Merck Sharp & Dohme; SeaGen<\/b> Other, Speaker fee.<br><b>V. Boni, <\/b> None..<br><b>D. Vincente Baz, <\/b> None..<br><b>A. Chaudhry, <\/b> None..<br><b>I. Gil Bazo, <\/b> None..<br><b>M. Gutierrez, <\/b> None..<br><b>J. Malhotra, <\/b> None..<br><b>C. Guzman Alonso, <\/b> None..<br><b>V. Gambardella, <\/b> None.&nbsp;<br><b>M. Chisamore, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment. <br><b>R. Zhou, <\/b> <br><b>Zai Lab (US) LLC<\/b> Employment, Stock, Stock Option. <br><b>M. Tea, <\/b> <br><b>Zai Lab (US) LLC<\/b> Employment, Stock, Stock Option.<br><b>D. Doroshow, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11629","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT162","PresenterBiography":null,"PresenterDisplayName":"Muy Kheng Tea, MD","PresenterKey":"b8f7f0ad-e4f8-4735-9c20-231280c42bad","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT162. Trial in progress: A phase I, open-label, multicenter study of ZL-1218, an anti-CCR8 IgG1, as a single agent and as combination therapy with anti-PD-1 antibody to evaluate the safety, tolerability, and pharmacokinetics in subjects with advanced solid tumor","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Trial in progress: A phase I, open-label, multicenter study of ZL-1218, an anti-CCR8 IgG1, as a single agent and as combination therapy with anti-PD-1 antibody to evaluate the safety, tolerability, and pharmacokinetics in subjects with advanced solid tumor","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Targeted therapy,Ras,Phase I,Solid tumors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>G. J. Hanna<\/b><sup>1<\/sup>, D. R. Adkins<sup>2<\/sup>, J. S. Thomas<sup>3<\/sup>, J. Y. Bruce<sup>4<\/sup>, M. R. Patel<sup>5<\/sup>, G. Sonpavde<sup>6<\/sup>, J. Henry<sup>7<\/sup>, N. Bendris<sup>8<\/sup>, Z. Zhang<sup>8<\/sup>, A. Mitra<sup>8<\/sup>, A. Gascó<sup>8<\/sup>, A. Saunders<sup>8<\/sup>, S. Dale<sup>8<\/sup>; <br\/><sup>1<\/sup>Dana-Farber Cancer Institute, Boston, MA, <sup>2<\/sup>Washington University School of Medicine, St. Louis, MO, <sup>3<\/sup>University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, <sup>4<\/sup>University of Wisconsin Carbone Cancer Center, Madison, WI, <sup>5<\/sup>Florida Cancer Specialists, Sarah Cannon Research Institute, Sarasota, FL, <sup>6<\/sup>AdventHealth Cancer Institute and the University of Central Florida, Orlando, FL, <sup>7<\/sup>Sarah Cannon Research Institute, Denver, CO, <sup>8<\/sup>Kura Oncology, Boston, MA","CSlideId":"","ControlKey":"d1bb7e5f-6da1-462d-b5ea-54a8e53b9c2a","ControlNumber":"10415","DisclosureBlock":"<b>&nbsp;G. J. Hanna, <\/b> <br><b>Actuate; Bicara; Bristol-Myers Squibb; Elevar; Exicure; Genentech; GlaxoSmithKline; ImmunityBio; Kartos; Kite; KSQ; Kura Oncology; Regeneron; Repertoire; Sanofi Genzyme; Secura Bio<\/b> Grant\/Contract. <br><b>Bicara; Boxer Capital, Coherus; Elevar; General Catalyst; Guardian Bio; Inibrix; KSQ; Kura Oncology; Merck; Naveris; Nextech; PDS Biotech; Remix; Replimune; Surface Oncology<\/b> Other, Consulting, Advisory Boards and Honoraria. <br><b>D. R. Adkins, <\/b> <br><b>Kura, Merck, Blueprint Medicines, Boehringer Ingelheim, Cue Biopharma, Coherus, Eisai, Exelixis, twoXAR, Vaccinex, Immunitas, Natco Pharma, TargImmune Therapeutics, and Xilio<\/b> Other, Consulting\/scientific advisory board. <br><b>Kura, Pfizer, Eli Lilly, Merck, Celgene\/BMS, Novartis, AstraZeneca, Blueprint Medicine, Celldex, Enzychem,  Exelixis, Innate, Debiopharm International, ISA Therapeutics, Gilead Sciences, BeiGene, Roc<\/b> Grant\/Contract. <br><b>Natco Pharma<\/b> Travel. <br><b>J. S. Thomas, <\/b> <br><b>Tasly pharmaceuticals, Inc.<\/b> Other, Consulting. <br><b>J. Y. Bruce, <\/b> <br><b>Kura Oncology<\/b> Other, Safety monitoring committee. <br><b>M. R. Patel, <\/b> <br><b>Janssen Oncology<\/b> Other, Honorarium. <br><b>Olema Pharmaceuticals; Daiichi Sankyo\/UCB Japan; Accutar Biotech<\/b> Other, Consulting\/advisory role. <br><b>Acerta; ADC Therapeutics; Agenus; Alleron; AstraZeneca; BioNTech AG; Boehringer Ingelheim; Celgene; CicloMed; Clovis Oncology; Cyteir Therapeutics; Daiichi Sankyo; Lilly; Evelo Therapeutics<\/b> Other, Research funding to institution. <br><b>Genentech\/Roche; Gilead Sciences; GlaxoSmithKline; H3 Biomedicine; Hengrui; Hutchinson MediPharma; Jacobio; Janssen; Klus; Kura Oncology; Kymab; Loxo; LSK Biopartners; Lycera; Macrogenics; Merck<\/b> Other, Research funding to institution. <br><b>Millennium; Mirati; Moderna; Pfizer; Prelude Therapeutics; Ribon Therapuetics; Seven and Eight Biopharmaceuticals; Syndax; Taiho; Tesaro; TopAlliance Biosciences; Vigeo; ORIC; Artios; Treadwell;<\/b> Other, Research funding to institution. <br><b>Mabspace; IgM Biosciences; Puretech; Artios; BioTheryX; Black Diamond Therapeutics; NGM Biopharmaceuticals; Novarits; Nurix; Relay Therapeutics; Samumed; Silicon; TeneoBio; Zymeworks; Adagene<\/b> Other, Research funding to institution. <br><b>NGM; Accutar Biotech; Compugen; Immunogen; Blueprint Pharmaceuticals; Bayer; Bicycle Therapeutics; Cullinan Oncology; Erasca, Inc.; Immune-Onc Therapeutics; Immunitas; Jazz Pharmaceuticals; Pionyr<\/b> Other, Research funding to institution. <br><b>Revolution Medicine; Step Pharma; Synthorx; Xencor; Briston-Myers Squibb\/Celgene; Incyte; Kineta; Hotspot Therapeutics; Conjupro Biotherapeutics; Allorion Therapeutics<\/b> Other, Research funding to institution. <br><b>G. Sonpavde, <\/b> <br><b>BMS, Genentech, EMD Serono, Merck, Astrazeneca, Sanofi, Seattle Genetics\/Astellas, Astrazeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly\/Loxo<\/b> Other, Advisory Board. <br><b>Suba Therapeutics, Syapse, Servier, Merck, Syncorp<\/b> Other, Consultant\/Scientific Advisory Board. <br><b>Sanofi, Astrazeneca, Gilead, Helsinn, Lucence, BMS, EMD Serono, Jazz Therapeutics<\/b> Other, Research support to institution. <br><b>BIO – INFORMAÇÃO BRASILEIRA DE ONCOLOGIA Ltda, OLE Forum (Mexico), Seagen, Gilead, Natera, Exelixis, Janssen, Bayer, Aveo<\/b> Other, Speaker. <br><b>Mereo<\/b> Other, Data safety monitoring committee honorarium. <br><b>Myriad<\/b> Other, Spouse employment. <br><b>Uptodate, Practice Update, Onviv<\/b> Other, Writing\/Editor fees.<br><b>J. Henry, <\/b> None.&nbsp;<br><b>N. Bendris, <\/b> <br><b>Kura Oncology<\/b> Employment. <br><b>Z. Zhang, <\/b> <br><b>Kura Oncology<\/b> Employment. <br><b>A. Mitra, <\/b> <br><b>Kura Oncology<\/b> Employment. <br><b>A. Gascó, <\/b> <br><b>Kura Oncology<\/b> Employment. <br><b>A. Saunders, <\/b> <br><b>Kura Oncology<\/b> Employment. <br><b>S. Dale, <\/b> <br><b>Kura Oncology<\/b> Employment.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11630","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT163","PresenterBiography":null,"PresenterDisplayName":"Glenn Hanna, MD","PresenterKey":"b2aeecee-5d4e-48fd-baa3-05e886537d55","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT163. FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Non-Hodgkin's lymphoma,TP53,DNA damage,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Zhou<\/b>, R. Ewesuedo, G. Agnello, A. Kulkarni, K. Bhatia; <br\/>Lantern Pharma Inc., Dallas, TX","CSlideId":"","ControlKey":"2ac33c14-0d23-42ea-958d-124b20e474f3","ControlNumber":"9539","DisclosureBlock":"<b>&nbsp;J. Zhou, <\/b> <br><b>Lantern Pharma Inc.<\/b> Employment, Stock Option. <br><b>R. Ewesuedo, <\/b> <br><b>Lantern Pharma Inc.<\/b> Employment, Stock Option. <br><b>G. Agnello, <\/b> <br><b>Lantern Pharma Inc.<\/b> Employment. <br><b>A. Kulkarni, <\/b> <br><b>Lantern Pharma Inc.<\/b> Employment, Stock Option. <br><b>K. Bhatia, <\/b> <br><b>Lantern Pharma Inc.<\/b> Employment, Stock Option.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11631","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT164","PresenterBiography":null,"PresenterDisplayName":"Jianli Zhou","PresenterKey":"829296ef-cf09-4b80-acab-1f891f9dea4e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT164. Phase 1a\/1b clinical trial of LP-284, a highly potent TP53 mutation agnostic DNA damaging agent, in patients with refractory or relapsed lymphomas and solid tumors (NCT06132503)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1a\/1b clinical trial of LP-284, a highly potent TP53 mutation agnostic DNA damaging agent, in patients with refractory or relapsed lymphomas and solid tumors (NCT06132503)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Solid tumors,B7-H3,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y. Cheng<\/b><sup>1<\/sup>, A. Lisberg<sup>2<\/sup>, C. Lemech<sup>3<\/sup>, A. Abed<sup>4<\/sup>, A. Chaudhry<sup>5<\/sup>, A. Schmidt<sup>6<\/sup>, X. Lu<sup>7<\/sup>, Z. Zhu<sup>7<\/sup>, W. Gu<sup>7<\/sup>, Y. Qiu<sup>8<\/sup>, R. Shi<sup>9<\/sup>, B. Zhang<sup>7<\/sup>; <br\/><sup>1<\/sup>Jilin Provincial Cancer Hospital, Changchun, China, <sup>2<\/sup>University of California, Los Angeles, Los Angeles, CA, <sup>3<\/sup>Scientia Clinical Research, Randwick, Australia, <sup>4<\/sup>Linear Clinical Research, Nedlands, Australia, <sup>5<\/sup>Summit Cancer Centers, Spokane, WA, <sup>6<\/sup>Sunshine Coast University Private Hospital, Birtinya, Australia, <sup>7<\/sup>Duality Biologics, Shanghai, China, <sup>8<\/sup>Duality Biologics, Basking Ridge, NJ, <sup>9<\/sup>Duality Biologics, Princeton, NJ","CSlideId":"","ControlKey":"c97df7ff-a9f6-4e4b-924c-cfae16a8a161","ControlNumber":"9797","DisclosureBlock":"&nbsp;<b>Y. Cheng, <\/b> None..<br><b>A. Lisberg, <\/b> None..<br><b>C. Lemech, <\/b> None..<br><b>A. Abed, <\/b> None..<br><b>A. Chaudhry, <\/b> None..<br><b>A. Schmidt, <\/b> None..<br><b>X. Lu, <\/b> None..<br><b>Z. Zhu, <\/b> None..<br><b>W. Gu, <\/b> None..<br><b>Y. Qiu, <\/b> None..<br><b>R. Shi, <\/b> None..<br><b>B. Zhang, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11632","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT165","PresenterBiography":null,"PresenterDisplayName":"Cuixia Gao","PresenterKey":"48c2ea9f-8766-4037-9d70-1581d1175e6e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT165. A phase 1\/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced\/metastatic solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 1\/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced\/metastatic solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Targeted drug delivery,Small molecule drugs,SN-38,Solid tumors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"H.-C. Wang<sup>1<\/sup>, Y.-M. Yeh<sup>2<\/sup>, J.-S. Du<sup>1<\/sup>, T.-J. Yeh<sup>1<\/sup>, J.-H. Tsai<sup>3<\/sup>, Y.-C. Gau<sup>1<\/sup>, S. Wu<sup>2<\/sup>, L.-T. Chen<sup>1<\/sup>, <b>H.-F. Li<\/b><sup>4<\/sup>, W.-C. Su<sup>2<\/sup>; <br\/><sup>1<\/sup>Kaohsiung Medical University Hospital, Kaohsiung city, Taiwan, <sup>2<\/sup>National Cheng Kung University Hospital, Tainan, Taiwan, <sup>3<\/sup>National Cheng-Kung University Hospital, Tainan, Taiwan, <sup>4<\/sup>Taivex Therapeutics Corporation, Taipei city, Taiwan","CSlideId":"","ControlKey":"cb8a1c13-d22f-4222-8b46-352d7afbc5e8","ControlNumber":"9513","DisclosureBlock":"&nbsp;<b>H. Wang, <\/b> None..<br><b>Y. Yeh, <\/b> None..<br><b>J. Du, <\/b> None..<br><b>T. Yeh, <\/b> None..<br><b>J. Tsai, <\/b> None..<br><b>Y. Gau, <\/b> None..<br><b>S. Wu, <\/b> None.&nbsp;<br><b>L. Chen, <\/b> <br><b>SynCore, TTY, Polaris, ACT genomics, Pfizer, BMS, Novatis, Merck Serono<\/b> Grant\/Contract. <br><b>HuniLife, Taiwan<\/b> Other, Royalties. <br><b>PharmaEngine, Taivex, OBI<\/b> Honoraria. <br><b>ONO, BMS, Eli Lilly, MSD, Ipsen, TTY, SynCore, Novatis, AstraZeneca, CStone, Astellas, Taivex<\/b> Other, Advisory\/Consultancy. <br><b>ScinoPharm Taiwan, Ltd<\/b> Other, Board of Derector. <br><b>H. Li, <\/b> <br><b>Taivex Therapeutics Corporation<\/b> Employment.<br><b>W. Su, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11633","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT166","PresenterBiography":null,"PresenterDisplayName":"Hsiao-Fang Li, PhD","PresenterKey":"860e85c5-c041-4ebb-89ff-e22290a24920","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT166. First-in-human phase 1 study of a phosphatidylserine-targeting small molecule drug conjugate (T-1201) in patients with advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First-in-human phase 1 study of a phosphatidylserine-targeting small molecule drug conjugate (T-1201) in patients with advanced solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Small molecule drugs,Solid tumors,Oncogene,Cell proliferation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"W.-C. Su<sup>1<\/sup>, L.-Y. Bai<sup>2<\/sup>, H.-H. Hsiao<sup>3<\/sup>, H.-S. Shiah<sup>4<\/sup>, Y.-M. Yeh<sup>1<\/sup>, S.-H. Chen<sup>5<\/sup>, S.-Y. Wu<sup>1<\/sup>, H.-C. Wang<sup>3<\/sup>, H.-J. Tsai<sup>5<\/sup>, K.-Y. Chang<sup>5<\/sup>, J.-H. Tsai<sup>6<\/sup>, C.-H. Lee<sup>6<\/sup>, <b>C. Lee<\/b><sup>7<\/sup>, Y.-S. Chao<sup>7<\/sup>, L.-T. Chen<sup>3<\/sup>; <br\/><sup>1<\/sup>Department of Oncology, National Cheng Kung University Hospital, Tainan, Taiwan, <sup>2<\/sup>Department of Hematology and Oncology, China Medical University Hospital, Taichung, Taiwan, <sup>3<\/sup>Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, <sup>4<\/sup>Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, <sup>5<\/sup>National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan, <sup>6<\/sup>Division of Hematology Oncology, Department of Internal Medicine, National Cheng-Kung University Hospital, Tainan, Taiwan, <sup>7<\/sup>Taivex Therapeutics Corporation, Taipei, Taiwan","CSlideId":"","ControlKey":"759e841a-eb83-4a2c-8dfd-d2485634a632","ControlNumber":"9789","DisclosureBlock":"&nbsp;<b>W. Su, <\/b> None..<br><b>L. Bai, <\/b> None..<br><b>H. Hsiao, <\/b> None..<br><b>H. Shiah, <\/b> None..<br><b>Y. Yeh, <\/b> None..<br><b>S. Chen, <\/b> None..<br><b>S. Wu, <\/b> None..<br><b>H. Wang, <\/b> None..<br><b>H. Tsai, <\/b> None..<br><b>K. Chang, <\/b> None..<br><b>J. Tsai, <\/b> None..<br><b>C. Lee, <\/b> None..<br><b>C. Lee, <\/b> None..<br><b>Y. Chao, <\/b> None.&nbsp;<br><b>L. Chen, <\/b> <br><b>PharmaEgine; Taivex; OBI<\/b> Other, Honoraria (self). <br><b>ONO; BMS; Eli Lilly; MSD; Ipsen; TTY; Syncore; Novartis; AstraZeneca; CStone; Astellas; Taivex<\/b> Other, Advisory \/ Consultancy. <br><b>Syncore BioPharma; TTY; Polaris; ACT genomics;Pfizer; BMS; Novartis; Merck Serono<\/b> Other, Research grant \/ Funding (institution). <br><b>HuniLife, Taiwan<\/b> Other, Licensing \/ Royalties. <br><b>Kaohsiung Medical University Hospital, Kaohsiung Medical University, Taiwan<\/b> Employment. <br><b>National Institute of Cancer Research, National Health Research Institutes, Taiwan<\/b> Employment. <br><b>ScinoPharm Taiwan, Ltd.<\/b> Other, Officer \/ Board of Directors:.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11634","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"18","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT167","PresenterBiography":null,"PresenterDisplayName":"Chieh Hua Lee, PhD","PresenterKey":"f9b4c10e-1a9d-4299-a7be-10b3ec275b78","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT167. Trial in progress: Phase 1 dose escalation study of T-1101, a first-in-class oral Hec1\/Nek2 inhibitor, in patients with advanced refractory solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Trial in progress: Phase 1 dose escalation study of T-1101, a first-in-class oral Hec1\/Nek2 inhibitor, in patients with advanced refractory solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Solid tumors,HER3,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. Lisberg<\/b><sup>1<\/sup>, S. Lu<sup>2<\/sup>, A. Starodub<sup>3<\/sup>, H. Amin<sup>4<\/sup>, J. Rotow<sup>5<\/sup>, L. Wu<sup>6<\/sup>, A. Spira<sup>7<\/sup>, E. Hamilton<sup>8<\/sup>, W. Shen<sup>9<\/sup>, L. Liu<sup>10<\/sup>, Z. Zhu<sup>9<\/sup>, W. Gu<sup>9<\/sup>, Y. Qiu<sup>11<\/sup>, R. Shi<sup>12<\/sup>, S. Liu<sup>9<\/sup>; <br\/><sup>1<\/sup>University of California, Los Angeles, Los Angeles, CA, <sup>2<\/sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China, <sup>3<\/sup>The Christ Hospital Cancer Center, Cincinnati, OH, <sup>4<\/sup>BRCR GLOBAL, Plantation, FL, <sup>5<\/sup>Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Boston, MA, <sup>6<\/sup>Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, <sup>7<\/sup>Virginia Cancer Specialists Research Institute, NEXT Oncology-Virginia, Fairfax, VA, <sup>8<\/sup>Sarah Cannon Research Institute, Nashville, TN, <sup>9<\/sup>Duality Biologics, Shanghai, China, <sup>10<\/sup>Duality Biologics, Philadelphia, PA, <sup>11<\/sup>Duality Biologics, Basking Ridge, NJ, <sup>12<\/sup>Duality Biologics, Princeton, NJ","CSlideId":"","ControlKey":"31c52797-a7e7-4a66-bdf2-6a44353c8cad","ControlNumber":"9790","DisclosureBlock":"&nbsp;<b>A. Lisberg, <\/b> None..<br><b>S. Lu, <\/b> None..<br><b>A. Starodub, <\/b> None..<br><b>H. Amin, <\/b> None..<br><b>J. Rotow, <\/b> None..<br><b>L. Wu, <\/b> None..<br><b>A. Spira, <\/b> None..<br><b>E. Hamilton, <\/b> None..<br><b>W. Shen, <\/b> None..<br><b>L. Liu, <\/b> None..<br><b>Z. Zhu, <\/b> None..<br><b>W. Gu, <\/b> None..<br><b>Y. Qiu, <\/b> None..<br><b>R. Shi, <\/b> None..<br><b>S. Liu, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11635","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"19","PosterboardNumber":"19","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT168","PresenterBiography":null,"PresenterDisplayName":"Cuixia Gao","PresenterKey":"48c2ea9f-8766-4037-9d70-1581d1175e6e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT168. A phase 1\/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1310 (a HER3-targeting ADC) in patients with advanced\/metastatic solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 1\/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1310 (a HER3-targeting ADC) in patients with advanced\/metastatic solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"PARP inhibitors,Solid tumors,Microhomology-mediated end joining,DNA polymerase theta inhibitor,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"V. Samnotra<sup>1<\/sup>, V. Moroz<sup>2<\/sup>, L. Shtessel<sup>3<\/sup>, M. Kuchimanchi<sup>1<\/sup>, P. Hanafin<sup>4<\/sup>, M. Pannirselvam<sup>1<\/sup>, A. Bhaskar<sup>4<\/sup>, A. Liu<sup>5<\/sup>, H. Yuzugullu<sup>1<\/sup>, M. Barve<sup>6<\/sup>, D. Sommerhalder<sup>7<\/sup>, <b>T. Yap<\/b><sup>8<\/sup>, M. Sanicola-Nadel<sup>1<\/sup>; <br\/><sup>1<\/sup>GSK, Waltham, MA, <sup>2<\/sup>GSK, Stevenage, United Kingdom, <sup>3<\/sup>GSK, Durham, NC, <sup>4<\/sup>GSK, Collegeville, PA, <sup>5<\/sup>GSK, Uxbridge, United Kingdom, <sup>6<\/sup>Mary Crowley Cancer Research, Dallas, TX, <sup>7<\/sup>Texas Oncology–San Antonio Babcock Next Oncology, San Antonio, TX, <sup>8<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"d6761b4b-d30e-4bff-830b-6951a4da4f06","ControlNumber":"9686","DisclosureBlock":"<b>&nbsp;V. Samnotra, <\/b> <br><b>GSK<\/b> Employment, Stock, Stock Option. <br><b>V. Moroz, <\/b> <br><b>GSK<\/b> Employment, Stock, Stock Option. <br><b>L. Shtessel, <\/b> <br><b>GSK<\/b> Employment, Stock, Stock Option. <br><b>M. Kuchimanchi, <\/b> <br><b>GSK<\/b> Employment, Stock, Stock Option. <br><b>P. Hanafin, <\/b> <br><b>GSK<\/b> Employment, Stock, Stock Option. <br><b>M. Pannirselvam, <\/b> <br><b>GSK<\/b> Employment, Stock, Stock Option. <br><b>A. Bhaskar, <\/b> <br><b>GSK<\/b> Employment, Stock, Stock Option. <br><b>A. Liu, <\/b> <br><b>GSK<\/b> Employment, Stock, Stock Option. <br><b>H. Yuzugullu, <\/b> <br><b>GSK<\/b> Employment, Stock, Stock Option. <br><b>M. Barve, <\/b> <br><b>Agenus<\/b> Travel. <br><b>Texas Oncology<\/b> Stock. <br><b>D. Sommerhalder, <\/b> <br><b>Texas Oncology<\/b> Employment, Stock. <br><b>NEXT Oncology<\/b> Stock. <br><b>Syneos<\/b> Other, Honoraria. <br><b>Guidepoint<\/b> Other, Consulting Fees. <br><b>AbbVie, ADC Therapeutics, Ascentage Pharma Group, Astellas, Biomea Fusion, BioNTech, BJ Bioscience, Boehringer Ingelheim, Fate Therapeutics, Gilead Sciences, Haihe Pharmaceutical, Iconovir Bio<\/b> Grant\/Contract. <br><b>Immuneering, Impact Therapeutics, Kura Oncology, MediLink Therapeutics, Mirati Therapeutics, Monopteros Therapeutics, Navire Pharma, NGM Biopharmaceuticals, Nimbus Saturn, OncoResponse<\/b> Grant\/Contract. <br><b>Parthenon, Pfizer, Revolution Medicines, Symphogen, Tachyon Therapeutics, Teon Therapeutics, Vincerx Pharma, and ZielBio<\/b> Grant\/Contract. <br><b>T. Yap, <\/b> <br><b>Texas MD Anderson Cancer Center<\/b> Employment, Other, University of Texas MD Anderson Cancer Center has a commercial interest in DDR and other inhibitors (IACS30380\/ART0380 was licensed to Artios). <br><b>858 Therapeutics, AbbVie, Acrivon, Adagene, Aduro, Almac, Amphista, Artios, Astex, AstraZeneca, Athena, Atrin, Avenzo, Avoro, Axiom, Baptist Health Systems, Bayer, Beigene, BioCity Pharma, Blueprint<\/b> Other, Consulting Fees. <br><b>Boxer, Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Carrick Therapeutics, Circle Pharma, Clovis, Cybrexa, Daiichi Sankyo, Dark Blue Therapeutics, Diffusion, Duke Street Bio<\/b> Other, Consulting Fees. <br><b>EcoR1 Capital, Ellipses Pharma, EMD Serono, Entos, F-Star, Genesis Therapeutics, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Ideaya Biosciences, Idience, Ignyta, I-Mab, ImmuneSensor<\/b> Other, Consulting Fees. <br><b>Impact Therapeutics, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI Pharma, Mereo, Merck, Merit, Monte Rosa Therapeutics, Natera, Nested Therapeutics, Nexys, Nimbus, Novocure, Odyssey<\/b> Other, Consulting Fees. <br><b>OHSU, OncoSec, Ono Pharma, Onxeo, PanAngium Therapeutics, Pegascy, PER, Pfizer, Piper-Sandler, Pliant Therapeutics, ProLynx, Protai Bio, Radiopharm Theranostics, Repare, resTORbio, Roche<\/b> Other, Consulting Fees. <br><b>Ryvu Therapeutics, SAKK, Sanofi, Schrodinger, Servier, Synnovation, Synthis Therapeutics, Tango, TCG Crossover, TD2, Terremoto Biosciences, Tessellate Bio, Theragnostics, Terns Pharmaceuticals<\/b> Other, Consulting Fees. <br><b>Tolremo, Tome, Thryv Therapeutics, Trevarx Biomedical, Varian, Veeva, Versant, Vibliome, Voronoi, XinThera, Zai Labs, and ZielBio<\/b> Other, Consulting Fees. <br><b>Acrivon, Artios, AstraZeneca, Bayer, BeiGene, BioNTech, Blueprint, BMS, Boundless Bio, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, Genentech, GSK, Haihe, Ideaya<\/b> Grant\/Contract. <br><b>ImmuneSensor, Insilico Medicine, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics<\/b> Grant\/Contract. <br><b>Tango, Tesaro, Vivace, and Zenith<\/b> Grant\/Contract. <br><b>Seagen<\/b> Stock. <br><b>M. Sanicola-Nadel, <\/b> <br><b>GSK<\/b> Employment, Stock, Stock Option.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11636","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"20","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT169","PresenterBiography":null,"PresenterDisplayName":"Timothy Yap, MD;PhD","PresenterKey":"0715e96f-8ae5-4415-aeac-574b964cb9d9","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT169. First-in-human, phase 1\/2 study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First-in-human, phase 1\/2 study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"T cell,Cytotoxic T lymphocytes,Adoptive Cell Therapy,Phase 1 clinical trial,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Moser<\/b><sup>1<\/sup>, B. Pico<sup>2<\/sup>, B. Henick<sup>3<\/sup>, R. Leidner<sup>4<\/sup>, J. Weiss<sup>5<\/sup>, J. Isaacs<sup>6<\/sup>, J. Grewal<sup>7<\/sup>, M. Hurwitz<sup>8<\/sup>, J. Murray<sup>9<\/sup>, M. Motta<sup>9<\/sup>, Y. Wang<sup>9<\/sup>, S. Chattopadhyay<sup>9<\/sup>, D. Barton<sup>9<\/sup>, G. MacBeath<sup>9<\/sup>, S. Thomas<sup>10<\/sup>; <br\/><sup>1<\/sup>HonorHealth Research & Innovation Institute, Scottsdale, AZ, <sup>2<\/sup>Memorial Healthcare System, Hollywood, FL, <sup>3<\/sup>Columbia University, New York, NY, <sup>4<\/sup>Providence Cancer Institute, Earle A. Chiles Research Institute, Providence, OR, <sup>5<\/sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, <sup>6<\/sup>The Cleveland Clinic, Cleveland, OH, <sup>7<\/sup>Norton Cancer Institute, Louisville, KY, <sup>8<\/sup>Yale, New Haven, CT, <sup>9<\/sup>TScan Therapeutics, Waltham, MA, <sup>10<\/sup>Orlando Health, Orlando, FL","CSlideId":"","ControlKey":"297b8b3f-a6ad-4185-b802-61bdfc5d81f8","ControlNumber":"10577","DisclosureBlock":"&nbsp;<b>J. Moser, <\/b> None..<br><b>B. Pico, <\/b> None..<br><b>B. Henick, <\/b> None.&nbsp;<br><b>R. Leidner, <\/b> <br><b>BMS<\/b> Grant\/Contract, Travel. <br><b>Incyte<\/b> Grant\/Contract. <br><b>AZ<\/b> Grant\/Contract. <br><b>Merck<\/b> Other, Advisory. <br><b>Vir<\/b> Other, Advisory. <br><b>CDR-Life<\/b> Other, advisory.<br><b>J. Weiss, <\/b> None..<br><b>J. Isaacs, <\/b> None..<br><b>J. Grewal, <\/b> None..<br><b>M. Hurwitz, <\/b> None.&nbsp;<br><b>J. Murray, <\/b> <br><b>TScan Therapeutics<\/b> Employment, Stock Option. <br><b>M. Motta, <\/b> <br><b>TScan Therapeutics<\/b> Employment, Stock Option. <br><b>Y. Wang, <\/b> <br><b>TScan Therapeutics<\/b> Employment, Stock Option. <br><b>S. Chattopadhyay, <\/b> <br><b>TScan Therapeutics<\/b> Employment, Stock Option. <br><b>D. Barton, <\/b> <br><b>TScan Therapeutics<\/b> Employment, Stock Option. <br><b>G. MacBeath, <\/b> <br><b>TScan Therapeutics<\/b> Employment, Stock Option.<br><b>S. Thomas, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11637","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"21","PosterboardNumber":"21","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT170","PresenterBiography":null,"PresenterDisplayName":"Justin Moser, MD","PresenterKey":"ae08fc31-cc1a-40c6-a221-f89b47f00f2b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT170. Trial in progress: A phase 1, first in human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"620","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 2","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Trial in progress: A phase 1, first in human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors","Topics":null,"cSlideId":""}]